Citation: Panagiotis Vlamos. Novel modeling methodologies for the neuropathological dimensions of Parkinson's disease[J]. AIMS Neuroscience, 2020, 7(2): 89-93. doi: 10.3934/Neuroscience.2020006
[1] | Wakabayashi K, Tanji K, Mori F, et al. (2007) The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27: 494-506. doi: 10.1111/j.1440-1789.2007.00803.x |
[2] | Aitken M, Clancy B, Nass D (2017) The Growing Value of Digital Health Evidence and Impact on Human Health and the Healthcare System. IQVIA Available from: https://www.iqvia.com/institute/reports/the-growing-val-ue-of-digital-health. |
[3] | Bazazeh D, Shubair R, Malik W (2016) Biomarker discovery and validation for Parkinson's Disease: A machine learning approach. |
[4] | Nilashi M, Ibrahim O, Ahmadi H, et al. (2018) A hybrid intelligent system for the prediction of Parkinson's Disease progression using machine learning techniques. Biocybern Biomed Eng 38: 1-15. doi: 10.1016/j.bbe.2017.09.002 |
[5] | Smits L, Reinhardt L, Reinhardt P, et al. (2019) Modeling Parkinson's disease in midbrain-like organoids. NPJ Parkinson Dis 5: 1-8. doi: 10.1038/s41531-019-0074-8 |
[6] | Cooper J, Van Raamsdonk J (2018) Modeling Parkinson's Disease in C. elegans. J Parkinson Dis 8: 17-32. doi: 10.3233/JPD-171258 |
[7] | Li H, Jiang H, Zhang B, et al. (2018) Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. J Parkinson Dis 8: 479-493. doi: 10.3233/JPD-181353 |
[8] | Bakshi S, Chelliah V, Chen C, et al. (2018) Mathematical Biology Models of Parkinson's Disease. CPT Pharmacometrics Systems Pharmacology 8: 77-86. doi: 10.1002/psp4.12362 |